Although there is evidence of the disruption of the cytoskeletal machinery in Alzheimer’s Disease due to the Aβ1–42 (and its effects on the proteins α-Tubulin, Vimentin and SMA)57,58, to our cognizance, this is the first consolidated network study to undisputedly connect ROR1 to Aβ1–42 treatment in AD, by showing its deregulation both at the transcript and protein levels. This evidence concerns the gene VIM and early-onset autosomal dominant Alzheimer disease.